Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 5.86 is 52% above its 5-year average of 3.86, around the middle of its 5-year range (0.26–13.78).
As of the fiscal period ended Tuesday, June 30, 2026. 18.42% above its 12-month average of 4.95.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.86.
CURRENT RATIO
5.86
CURRENT RATIO AVG TTM
4.95
CURRENT RATIO AVG 3Y
2.91
CURRENT RATIO AVG 5Y
3.86
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+18.42%
CURRENT VS 3Y AVG
+101.61%
CURRENT VS 5Y AVG
+51.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.57
median of 739 covered companies
CURRENT VS SECTOR MEDIAN
+64.28%
vs the sector median at left
CNS Pharmaceuticals, Inc.
Market Cap
$7.37M
Current Ratio
5.86
TTM Avg
4.95
3Y Avg
2.91
5Y Avg
3.86
Market Cap
$7.31M
Current Ratio
1.37
TTM Avg
4.18
3Y Avg
4.61
5Y Avg
4.18
Market Cap
$7.62M
Current Ratio
14.52
TTM Avg
3.29
3Y Avg
11.30
5Y Avg
10.20
Market Cap
$7.20M
Current Ratio
45.95
TTM Avg
58.73
3Y Avg
40.89
5Y Avg
40.89
Market Cap
$7.08M
Current Ratio
0.31
TTM Avg
1.26
3Y Avg
1.91
5Y Avg
5.47
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.37M | 5.86 | 4.95 | 2.91 | 3.86 |
| Longeveron Inc. (LGVN)vs › | $7.33M | 2.63 | 4.46 | 3.65 | 4.69 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 1.37 | 4.18 | 4.61 | 4.18 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.62M | 14.52 | 3.29 | 11.30 | 10.20 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | 45.95 | 58.73 | 40.89 | 40.89 |
| KALA BIO, Inc. (KALA)vs › | $7.07M | 6.88 | 3.46 | 4.15 | 4.60 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.31 | 1.26 | 1.91 | 5.47 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | 0.18 | 0.90 | 2.08 | 1.78 |
| GT Biopharma, Inc. (GTBP)vs › | $7.93M | 2.61 | 2.11 | 2.42 | 2.17 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.96M | 7.10 | 3.48 | 3.83 | 5.25 |
Current Ratio
5.86
Quick Ratio
5.86
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 5.86 |
| 2026-03-31 | 0.88 |
| 2025-12-31 | 1.98 |
| 2025-09-30 | 5.81 |
| 2025-06-30 | 10.22 |
| 2025-03-31 | 4.94 |
| 2024-12-31 | 3.43 |
| 2024-09-30 | 1.82 |
| 2024-06-30 | 0.32 |
| 2024-03-31 | 0.26 |
| 2023-12-31 | 0.26 |
| 2023-09-30 | 0.51 |
| 2023-06-30 | 1.52 |
| 2023-03-31 | 1.78 |
| 2022-12-31 | 2.55 |
| 2022-09-30 | 6.99 |
| 2022-06-30 | 12.34 |
| 2022-03-31 | 13.78 |
| 2021-12-31 | 3.50 |
| 2021-09-30 | 4.63 |
| 2021-06-30 | 7.58 |
| 2021-03-31 | 6.72 |
| 2020-12-31 | 8.13 |
| 2020-09-30 | 4.93 |
| 2020-06-30 | 15.14 |
| 2020-03-31 | 18.42 |
| 2019-12-31 | 25.38 |
| 2019-09-30 | 0.99 |
| 2019-06-30 | 1.27 |
| 2019-03-31 | 0.35 |
| 2018-12-31 | 0.48 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.75 |
| 2018-03-31 | 1.16 |
